Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuhan Dongkangyuan Technology is a Wuhan, China-based chemical and pharmaceutical raw material supplier that appears to operate primarily as a manufacturer and distributor of small-molecule compounds, including active pharmaceutical ingredients, intermediates, and research chemicals. Publicly available supplier listings describe the company as a high-tech enterprise focused on research, production, and sales of chemical raw materials, with an independent research base, testing capabilities, and export activity. Its catalogs list numerous pharmaceutical compounds such as capecitabine, tinidazole, telmisartan, febuxostat, dutasteride, and finasteride, suggesting a broad commercial supply business rather than a proprietary drug-development pipeline. Available evidence indicates it serves medicine manufacturers, research institutes, testing organizations, and industrial/scientific research customers. There is no clear evidence from the available sources that it is a venture-backed biotech with named clinical assets, novel therapeutic targets, or human clinical-stage programs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wuhan Dongkangyuan Technology.